Drug Profile

GI 5005

Alternative Names: GI-5005; Tarmogen

Latest Information Update: 14 Sep 2015

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator GlobeImmune
Class Antivirals; Hepatitis C vaccines
Mechanism of Action Immunostimulants; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Hepatitis C

Most Recent Events

03 Nov 2010 GlobeImmune receives grants under the Federal Therapeutics Discovery Projects programme for GI 5005 development in Hepatitis C
30 Oct 2010 Efficacy data from a phase IIb trial (GI-5005-02) in Hepatitis C presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2010)
28 Oct 2010 GlobeImmune expands phase IIb trial (GI-5005-02) for treatment-naive Hepatitis C to include patients with IL28B T/T genotype

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com